Multiple Myeloma Clinical Trials in Salamanca
32 recruitingSalamanca, Spain
Showing 1–20 of 32 trials
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 2Phase 3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
AbbVie660 enrolled38 locationsNCT07095452
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled87 locationsNCT05160584
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC140 enrolled14 locationsNCT06768489
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Janssen Research & Development, LLC60 enrolled16 locationsNCT07149857
Recruiting
Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
Kite, A Gilead Company450 enrolled124 locationsNCT06413498
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled238 locationsNCT05020236
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 1Phase 2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Regeneron Pharmaceuticals149 enrolled32 locationsNCT05828511
Recruiting
Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company187 enrolled19 locationsNCT06153251
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Multiple MyelomaMyeloma
K36 Therapeutics, Inc.125 enrolled22 locationsNCT05651932
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Phase 1Phase 2
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
AstraZeneca226 enrolled36 locationsNCT06106945
Recruiting
Phase 2
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
De Novo Multiple MyelomaAnitocabtagene Autoleucel
PETHEMA Foundation30 enrolled10 locationsNCT07045909
Recruiting
Not Applicable
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110
Recruiting
Phase 2
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
High Risk Smoldering Multiple Myeloma
PETHEMA Foundation20 enrolled1 locationNCT06574126